windows of susceptibility
Recently Published Documents


TOTAL DOCUMENTS

69
(FIVE YEARS 27)

H-INDEX

14
(FIVE YEARS 4)

Author(s):  
Li Shang ◽  
Liren Yang ◽  
Wenfang Yang ◽  
Guilan Xie ◽  
Ruiqi Wang ◽  
...  

2021 ◽  
Vol 155 ◽  
pp. 106586
Author(s):  
Heng-Gui Chen ◽  
Qi Lu ◽  
Zhou-Zheng Tu ◽  
Ying-Jun Chen ◽  
Bin Sun ◽  
...  

2021 ◽  
Vol 15 (3) ◽  
Author(s):  
Michele Zemplenyi ◽  
Mark J. Meyer ◽  
Andres Cardenas ◽  
Marie-France Hivert ◽  
Sheryl L. Rifas-Shiman ◽  
...  

2021 ◽  
Vol 2021 (1) ◽  
Author(s):  
Michiel Arjen Van Den Dries ◽  
Laura Granés ◽  
Albert Ambrós ◽  
Anne Claire Binter ◽  
Jordi Segu Tell ◽  
...  

2021 ◽  
Author(s):  
Julia Anglen Bauer ◽  
Roberta F. White ◽  
Brent A. Coull ◽  
Christine Austin ◽  
Manuela Oppini ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
pp. 54-62
Author(s):  
Katarzyna Rygiel

Introduction: It has been observed that many toxic environmental agents increase risk, accelerate development, or deteriorate the course of breast cancer (BC). In particular, endocrine-disrupting chemicals (EDC) are harmful to endocrine receptor actions and signaling in the breast tissue. Usually, there is a long interval of time between the exposure to EDC and BC incidence, and this often represents a serious obstacle for effective BC prophylaxis. Notably, during certain periods of a woman’s life cycle, the BC risk is particularly elevated due to increased susceptibility to some EDC. These windows of susceptibility (WOS) include prenatal, puberty, pregnancy, and menopausal transition stages of a female’s life course. Four WOS have been considered as the most vulnerable periods for BC since the mammary gland undergoes the main anatomical and physiological transformations at those intervals. This means that during specific WOS, the EDC from the environment can have the most dangerous impact on BC risk and possible BC development later in a woman’s life. However, most clinical BC studies related to toxic environmental exposures have not been connected to the specific WOS. Therefore, the goal of this article is to briefly describe some important research results, focused on the links between EDC and BC, within four critical WOS. In addition, this mini-review outlines some useful biomarkers for further research and prophylaxis of BC and also for both the research community and the medical professionals. Conclusion: To bridge the gap in BC prevention, it is essential to recognize the links between EDC and BC within the critical WOS. Moreover, an integrative model of BC research, applying intermediate biomarkers, is necessary to determine the mechanisms of action of various EDC during critical periods in a woman’s lifespan. Hopefully, this will lead to progress in BC prevention.


Sign in / Sign up

Export Citation Format

Share Document